Notably, scFv-OA2-siRAPSYN treatments resulted in more potent anti-tumor effects than the siRNA without scFv region, further confirming the critical roles of anti-CD79B-scFv for specific targeting and subsequent gene silencing. This evidence concerns the gene CD79B and neoplasm.